The cancer Institute of New Jersey
New Brunswick, New Jersey 08903
0 studies enrolling now · 38 studies all time
What they study most
Breast Cancer, Breast Neoplasms, Cancer, Colorectal Cancer, Colorectal Carcinoma, Diamond Blackfan Anemia, Fallopian Tube Cancer, Hematologic Malignancies, Hodgkin's Disease, Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Leukemia, Pediatric
Studies at this site
- A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). — Stopped early
- A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer — Stopped early
- Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia — Completed
- The BEACON Study (Breast Cancer Outcomes With NKTR-102) — Completed
- Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer — Stopped early
- Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies. — Completed
- Phase I Combination Ixabepilone + Cisplatin — Completed
- Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma — Completed
- A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer — Completed
- Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia — Stopped early
- Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer — Completed
- Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration — Completed
- PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy — Completed
- Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML — Completed
- Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer — Stopped early
- Multimodality Phase II Study in Prostate Cancer — Stopped early
- A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease — Completed
- Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy — Completed
- Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) — Completed
- Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML — Completed
- Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma — Completed
- SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) — Completed
- A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) — Completed
- Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer — Stopped early
- Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer — Status unconfirmed
- Phase I Study of Patupilone and RAD001 — Completed
- TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer — Completed
- TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer — Completed
- MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma — Completed
- Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload — Completed
- First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients — Stopped early
- A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia — Stopped early
- A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC) — Stopped early
- A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma — Stopped early
- Study of XL820 Given Orally Daily to Subjects With Solid Tumors — Completed
- Study of XL820 in Adults With Solid Tumors — Completed
- Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma — Completed
- PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen — Status unconfirmed